Millipore

Millipore streamlines, closes plants

Maureen Martino — Wed, 17 Sep 2008 01:07:43 -0400

As part of a cost-cutting plan that will save $11 million to $15 million a year, Millipore is closing a plant in Lincoln Park, NJ and another in Nodinge, Sweden. The plant closures will be accompanied by 140 job cuts, and Millipore said it may close two more plants in the UK.

The downsizing is the result of falling revenue in the company's bioprocess division, which supplies the drug manufacturing industry and accounts for 40 percent of Millipore's business. After several major acquisitions, Millipore announced last year that it would increase its offering to drug manufacturers.

- see this report for more

Millipore expands in Missouri

Maureen Martino — Fri, 27 Jun 2008 11:34:52 -0400

Life science supplier Millipore is giving a $3.4 million boost to its St. Charles, Missouri facility, which is the headquarters for its drug discovery business unit. The company will add 60 more people to the current 187 headcount. "The...expansion will enable Millipore to keep pace with the growth of its worldwide drug discovery and development business, which provides products and services that help pharmaceutical and biotechnology companies discover, evaluate and develop drug candidates," the company said in a statement. Back in September Millipore announced plans to give itself a $1.6B makeover as life sciences supplier.

- take a look at Millipore's release

Millipore touts its efforts to go green

Thu, 08 May 2008 06:59:54 -0400

The life sciences equipment maker Millipore is looking extra green today. The company announced plans to reduce its carbon footprint by 20 percent. To do that, the company plans to close some inefficient facilities and upgrade others so that they use less energy.

"Both individuals and companies have to do something" to cut pollution, Millipore CEO Martin Madaus told the Boston Globe. "It's not just the right thing to do. In many countries, it will be part of legislation."

- read the report in the Boston Globe

ALSO NOTED: Millipore CEO gains $3.9M comp package;Terminal cancer patients enlisted in trials; and much more...

Wed, 26 Mar 2008 07:59:50 -0400

> It may not rival the big bucks earned by Big Pharma CEOs, but Millipore chief exec Martin Madaus took home a hefty pay package last year. He earned $3.9 million in compensation in 2007. That includes $742,307 in base pay, a bonus of $488,000 and options worth $2.6 million on the day they were granted. Report

> Which drug exec gets paid 140 percent more than the median among his peers? Cephalon CEO Frank Baldino (photo). He made a cool $13.5 million last year. That paycheck included a $1.2 million salary, $2.2 million in bonus, and $10.1 million in stock and options. Report

> Mortality rates at 494 hospitals around the country that participated in clinical trials for acute coronary syndrome declined. Report

> Frustrated by the long years of research needed to prove the effectiveness of a new cancer therapy, British officials have designated a network of 19 hospital units that will be allowed to administer early-stage experimental cancer drugs to terminal patients. Report

> Big Pharma companies are often quick to turn their backs on a drug that doesn't deliver strong data. But a series of these failed development programs have been resurrected by scientists who decided to search for the kind of genetic biomarkers that would define a group of patients who would respond positively. Report

> Manipulating insulin levels raises the level of the master gene-regulating protein SKN-1, significantly prolonging the lives of microscopic worms in one study. Report

> HistoRx and Eli Lilly have extended their technology agreement. Story

> Pfizer and GlaxoSmithKline have been marking up meds to increase their revenues, according to Thomson data. The two companies boosted wholesale prices by about 9 percent on their 10 best-sellers last year. Without those increases, Pfizer and GSK would have seen their sales drop by more than 10 percent. Report

> Pfizer is suing for Lipitor protection until 2016. Report

And Finally... Many in the medical community are at odds over the ethics of at-home bipolar gene tests currently on the market. Report

ALSO NOTED: CEO: Novartis plans big restructuring; Time notes advances in stem cells, genetics; MabThera trials produce positiv

Tue, 11 Dec 2007 06:59:50 -0500

> In October, Novartis announced some job cuts and management changes. Now, CEO Daniel Vasella says he's working on a sweeping overhaul of his company's org chart. Report

> Time magazine has come out with its list of the top 10 scientific breakthroughs of the year, listing stem cell research and the genetic sequencing activities of J. Craig Venter at the top. Report

> Roche says two mid-stage trials for MabThera demonstrated positive results in leukemia. Release

> Bristol-Myers Squibb and Gilead plan to collaborate on the commercialization of the HIV drug Atripla in Europe, once it is approved. Report

> Carigent Therapeutics of New Haven has rounded up $2 million in its first round to help develop nanotechnology for drug delivery. Report

> Two investors have put up $3 million for CDI Bioscience. Report

> Biovest International has borrowed $8.5 million to fund research into an experimental cancer therapy. Report

> Millipore and Novozymes today announced an agreement to develop, market, and sell new, animal-free cell culture supplements for biopharmaceutical manufacturing. Release

> Pfizer cleared a big milestone in India today: The company became the first to get patent protection for an AIDS drug there. Report

> When it comes to government spending on medical research, the EU is far behind the U.S. And some of the leaders in the field say it's time to catch up--fast. Report

And Finally… Concerns about safety are growing as the biohazard research field booms. Report

ALSO NOTED: EU panel recommends Bayer, GSK drugs; Novacea names new CEO; and much more...

Fri, 21 Sep 2007 06:59:50 -0400

> An EMEA advisory panel has issued six positive opinions on marketing applications for new drugs, paving the way for EU marketing approval. Report

> Chutes & Ladders: Novacea has elected John P. Walker as CEO. He will continue to serve the Chairman of the company. Release

> Dr. Anthony S. Fauci, the director of the National Institute of Allergy and Infectious Diseases has won the Lasker Prize. Report

> Millipore is expanding on its reputation as a filtration supplier to scientific labs around the globe. Report

> Generics may be the bane of Big Pharma, but they're inflation-fighting ninjas. Over the last 12 months, prescription drug prices edged up by a measly 1 percent--the lowest rate of inflation in three decades. Report

> Pfizer is looking to set up its Japanese R&D operation, previously slated for shutdown, as an independent company--with the help of a few investors, of course. Report

And Finally... An ancient mechanism for coping with stresses also gives cancer a boost. Release